Literature DB >> 16543537

Clinical insights into paraneoplastic cerebellar degeneration.

R Scheid1, R Voltz, S Briest, R Kluge, D Y von Cramon.   

Abstract

Neuroimaging is usually unremarkable in paraneoplastic cerebellar degeneration (PCD), at least in the early stages of the disease. A patient with proven PCD is reported in whom it could be shown that cerebellar atrophy evolved very rapidly and was present in early imaging studies. Even with the use of the whole spectrum of modern diagnostic tools, the underlying malignancy can be difficult to diagnose. In addition to mammography, MRI is recommended in these cases and repeat FDG-PET may be necessary.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16543537      PMCID： PMC2077487          DOI： 10.1136/jnnp.2005.082206

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  10 in total

Review 1.  Anti-Yo antibody-positive cerebellar degeneration associated with endometrial carcinoma: case report and review of the literature.

Authors:  S Brock; D Ellison; J Frankel; C Davis; T Illidge
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

2.  Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies.

Authors:  J E Hammack; D W Kimmel; B P O'Neill; V A Lennon
Journal:  Mayo Clin Proc       Date:  1990-11       Impact factor: 7.616

Review 3.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

Review 4.  Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature.

Authors:  Y Cao; J Abbas; X Wu; J Dooley; A L van Amburg
Journal:  Gynecol Oncol       Date:  1999-10       Impact factor: 5.482

5.  Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.

Authors:  I Rojas; F Graus; F Keime-Guibert; R Reñé; J Y Delattre; J M Ramón; J Dalmau; J B Posner
Journal:  Neurology       Date:  2000-09-12       Impact factor: 9.910

6.  Paraneoplastic cerebellar degeneration: neurological symptoms pointing to occult ovarian cancer.

Authors:  P M Geomini; P L Dellemijn; G L Bremer
Journal:  Gynecol Obstet Invest       Date:  2001       Impact factor: 2.031

7.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients.

Authors:  K Peterson; M K Rosenblum; H Kotanides; J B Posner
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

9.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

Authors:  Setareh Shams'ili; Joost Grefkens; Bertie de Leeuw; Martin van den Bent; Herbert Hooijkaas; Bronno van der Holt; Charles Vecht; Peter Sillevis Smitt
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

10.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.

Authors:  S Younes-Mhenni; M F Janier; L Cinotti; J C Antoine; F Tronc; V Cottin; P J Ternamian; P Trouillas; J Honnorat
Journal:  Brain       Date:  2004-09-10       Impact factor: 13.501
  10 in total
  10 in total

1.  Unusual MRI abnormalities in anti-Yo positive "pure" paraneoplastic cerebellar degeneration.

Authors:  John C McHugh; Niall Tubridy; Conor D Collins; Michael Hutchinson
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

2.  Paraneoplastic cerebellar degeneration: new insights into imaging and immunology.

Authors:  J H Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

3.  Consensus paper: radiological biomarkers of cerebellar diseases.

Authors:  Leonardo Baldarçara; Stuart Currie; M Hadjivassiliou; Nigel Hoggard; Allison Jack; Andrea P Jackowski; Mario Mascalchi; Cecilia Parazzini; Kathrin Reetz; Andrea Righini; Jörg B Schulz; Alessandra Vella; Sara Jane Webb; Christophe Habas
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

4.  Paraneoplastic cerebellar degeneration as a marker of endometrial cancer recurrence.

Authors:  Geoffrey Lie; Thomas Morley; Muhammad Chowdhury
Journal:  BMJ Case Rep       Date:  2016-05-18

Review 5.  Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.

Authors:  Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

6.  [Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies].

Authors:  M Frackowiak; M Kowar; Ch Sippel; K Wilhelm; Y-D Ko; A H Jacobs
Journal:  Nervenarzt       Date:  2020-02       Impact factor: 1.214

7.  Paraneoplastic cerebellar degeneration mimicking acute post-infectious cerebellitis.

Authors:  Yuval Karmon; Edna Inbar; Mario Cordoba; Natan Gadoth
Journal:  Cerebellum       Date:  2009-12       Impact factor: 3.847

8.  Paraneoplastic cerebellar degeneration and dermatomyositis as first manifestations of underlying breast malignancy: a report of two cases and a brief review of the subject.

Authors:  Ying Ru Yvonne Ng; Chunyin Derek Ho; Weng Leong Victor Ng; Su-Ming Tan
Journal:  Surg Case Rep       Date:  2015-07-16

9.  Anti-yo associated paraneoplastic cerebellar degeneration in a man with large cell cancer of the lung.

Authors:  Linda Hasadsri; James Lee; Bonnie H Wang; Lalitha Yekkirala; Mingtao Wang
Journal:  Case Rep Neurol Med       Date:  2013-09-19

Review 10.  Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.

Authors:  Anand Venkatraman; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2016-06-30       Impact factor: 4.511
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.